What is the current stock price of Neoleukin Therapeutics, Inc. (NLTX)?

As of the latest market data, Neoleukin Therapeutics, Inc. (NLTX) is trading at $3.49. The stock has seen a gain of 1.45% today.

Does Neoleukin Therapeutics, Inc. (NLTX) pay a dividend?

Based on current data, Neoleukin Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Neoleukin Therapeutics, Inc.?

The current market capitalization of Neoleukin Therapeutics, Inc. (NLTX) is approximately unavailable.

NLTX

Neoleukin Therapeutics, Inc.·Healthcare

3.49

1.454%(+0.05)

Market Closed

Last Updated: — ET

52W L: $3.4252W H: $18.80

NLTX NEWS

defenseworld.net

5d ago

Neoleukin Therapeutics (NASDAQ:NLTX) & Zymeworks (NASDAQ:ZYME) Critical Contrast

Neoleukin Therapeutics (NASDAQ: NLTX - Get Free Report) and Zymeworks (NASDAQ: ZYME - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends. Institutional and Insider Ownership 52.4% of Neoleukin Therapeutics

defenseworld.net

Feb 1

Reviewing Intellipharmaceutics International (OTCMKTS:IPCIF) & Neoleukin Therapeutics (NASDAQ:NLTX)

Valuation and Earnings This table compares Neoleukin Therapeutics and Intellipharmaceutics International"s revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56 million ($3.11) -5.68 Intellipharmaceutics International $660,000.00 0.00 -$2.89 million ($0.16) N/A Intellipharmaceutics International has higher revenue and earnings than Neoleukin Therapeutics.

Company Profile

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

IPO Date

2014-03-07

Beta

1.10

Websitewww.neoleukin.com↗